Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00408-020-00393-8 http://scihub22266oqcxt.onion/10.1007/s00408-020-00393-8 32918573!7486805!32918573     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32918573&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Lung 2020 ; 198 (5): 777-784 Nephropedia Template TP {{tp|p=32918573|t=2020. Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19?|pdf=|usr=}}{{32918573}} gab.com Text Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19 JO: Lung http://www.kidney.de/pget.php?&tw=1&pmid=32918573 #FOAvip PURPOSE: SARS-CoV-2 (COVID-19) has infected more than 7 million people worldwide in the short time since it emerged in Wuhan, China in December 2019. The aim of this study was to investigate the relationship between serum interleukin 6 (IL-6) and surfactant protein D (SP-D) levels and the clinical course and prognosis of COVID-19. MATERIALS AND METHODS: The study included a total of 108 individuals: 88 patients who were diagnosed with COVID-19 by real-time PCR of nasopharyngeal swab samples and admitted to the Ataturk University Pulmonary Diseases and the Erzurum City Hospital Infectious Diseases department between March 24 and April 15, and 20 asymptomatic healthcare workers who had negative real-time PCR results during routine COVID-19 screening in our hospital. RESULTS: Patients who developed macrophage activation syndrome had significantly higher IL-6 and SP-D levels at the time of admission and on day 5 of treatment compared to the other patients (IL-6: p = 0.001 for both; SP-D: p = 0.02, p = 0.04). Patients who developed acute respiratory distress syndrome had significantly higher IL-6 and SP-D levels at both time points compared to those who did not (p = 0.001 for all). Both parameters at the time of admission were also significantly higher among nonsurvivors compared to survivors (IL-6: p = 0.001, SP-D: p = 0.03). CONCLUSION: In addition to IL-6, which has an important role in predicting course and planning treatment in COVID-19, SP-D may be a novel pneumoprotein that can be used in the clinical course, follow-up, and possibly in future treatments. Twit Text FOAVip Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19 ????Lung http://www.kidney.de/pget.php?&tw=1&pmid=32918573 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32918573 #FOAvip English Wikipedia <ref>{{Cite pmid|32918573}}</ref> Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19? #MMPMID32918573 Kerget B; Kerget F; Kocak AO; Kiziltunc A; Araz O; Ucar EY; Akgun M Lung 2020[Oct]; 198 (5): 777-784 PMID32918573show ga PURPOSE: SARS-CoV-2 (COVID-19) has infected more than 7 million people worldwide in the short time since it emerged in Wuhan, China in December 2019. The aim of this study was to investigate the relationship between serum interleukin 6 (IL-6) and surfactant protein D (SP-D) levels and the clinical course and prognosis of COVID-19. MATERIALS AND METHODS: The study included a total of 108 individuals: 88 patients who were diagnosed with COVID-19 by real-time PCR of nasopharyngeal swab samples and admitted to the Ataturk University Pulmonary Diseases and the Erzurum City Hospital Infectious Diseases department between March 24 and April 15, and 20 asymptomatic healthcare workers who had negative real-time PCR results during routine COVID-19 screening in our hospital. RESULTS: Patients who developed macrophage activation syndrome had significantly higher IL-6 and SP-D levels at the time of admission and on day 5 of treatment compared to the other patients (IL-6: p = 0.001 for both; SP-D: p = 0.02, p = 0.04). Patients who developed acute respiratory distress syndrome had significantly higher IL-6 and SP-D levels at both time points compared to those who did not (p = 0.001 for all). Both parameters at the time of admission were also significantly higher among nonsurvivors compared to survivors (IL-6: p = 0.001, SP-D: p = 0.03). CONCLUSION: In addition to IL-6, which has an important role in predicting course and planning treatment in COVID-19, SP-D may be a novel pneumoprotein that can be used in the clinical course, follow-up, and possibly in future treatments. |*Coronavirus Infections/blood/diagnosis/epidemiology[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/blood/diagnosis/epidemiology[MESH] |Betacoronavirus/*isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |Clinical Laboratory Techniques/methods[MESH] |Female[MESH] |Hospitalization/statistics & numerical data[MESH] |Humans[MESH] |Interleukin-6/*blood[MESH] |Male[MESH] |Middle Aged[MESH] |Predictive Value of Tests[MESH] |Prognosis[MESH] |Pulmonary Surfactant-Associated Protein D/*blood[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH]Are Serum Interleukin 6 and Surfactant Protein D Levels Associated wit(epmc).pdf DeepDyve Pubget Overpricing